Factors for graft‐versus‐host disease after donor lymphocyte infusions with an escalating dose regimen: lack of association with cell dose
Open Access
- 2 March 2007
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 136 (6) , 833-836
Abstract
We investigated the risk factors for graft‐versus‐host disease (GVHD) in 82 patients treated with donor lymphocyte infusions (DLI) using an escalating dose regimen for chronic myeloid leukaemia in relapse following conventional allografting. Two factors emerged as predictors of both acute and chronic GVHD: the infusion of male recipients with lymphocytes from a female donor and the interval between transplant and last DLI, but only the first remained significant at multivariate analysis. Surprisingly, lymphocyte dose did not influence the incidence of GVHD. Our results suggest that DLI can be given in large cell doses without increasing the risk of GVHD.Keywords
This publication has 10 references indexed in Scilit:
- Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid LeukemiaNew England Journal of Medicine, 2006
- Graft-versus-Host Reactions and the Effectiveness of Donor Lymphocyte InfusionsTransplantation and Cellular Therapy, 2006
- Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemiaLeukemia, 2003
- Prognostic factors for acute graft-versus-host disease after donor lymphocyte infusionsBlood, 2002
- Acute graft-versus-host disease does not require alloantigen expression on host epitheliumNature Medicine, 2002
- Donor Lymphocyte Infusions for Relapsed Multiple Myeloma After Allogeneic Stem-Cell Transplantation: Predictive Factors for Response and Long-Term OutcomeJournal of Clinical Oncology, 2000
- Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemiaBlood, 2000
- Bone marrow transplantation for chronic myeloid leukaemia: the effects of differing criteria for defining chronic phase on probabilities of survival and relapseBritish Journal of Haematology, 1997
- Mismatches of Minor Histocompatibility Antigens between HLA-Identical Donors and Recipients and the Development of Graft-Versus-Host Disease after Bone Marrow TransplantationNew England Journal of Medicine, 1996
- Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patientsBlood, 1990